Trial · NCT01265550
Registered outcomes54
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 54
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months | 12 months | Success; ≥50% improvement in the baseline GERD-HRQL score at 12 months. Failure; \<50% improvement in the baseline GERD-HRQL score at 12 months or: 1. For patients randomized to Surgical Treatment: a.\<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit. 2. For patients randomized to Active Medical or Placebo Medical Treatment: a.inability to tolerate both study medications or b.For patients treated with desipramine, i.\<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.\<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit. |
| Secondary | Number of Enrolled Participants With Esophageal Ulceration. | Screening | |
| Secondary | Number of Enrolled Participants With Reflux Esophagus. | Screening | |
| Secondary | Number of Enrolled Participants With Eosinophilic Esophagitis | Screening | |
| Secondary | Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum. | Screening | |
| Secondary | Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum | Screening | |
| Secondary | Number of Enrolled Participants With Candida Esophagitis. | Screening | |
| Secondary | Number of Enrolled Participants With Gastric Outlet Obstruction | Screening | |
| Secondary | Number of Enrolled Participants With Achalasia | Screening | |
| Secondary | Number of Enrolled Participants With Aperistalsis | Screening | |
| Secondary | Number of Enrolled Participants With Distal Esophageal Spasm | Screening | |
| Secondary | Number of Enrolled Participants With Nutcracker Esophagus | Screening | |
| Secondary | Number of Enrolled Participants With Ineffective Esophageal Motility | Screening | |
| Secondary | Number of Enrolled Participants With Rapid Contraction | Screening | |
| Secondary | Number of Enrolled Participants With Hypertensive Peristalsis | Screening | |
| Secondary | Number of Enrolled Participants With Jackhammer Esophagus | Screening | |
| Secondary | Number of Enrolled Participants With Weak Peristalsis I | Screening | |
| Secondary | Number of Enrolled Participants With Weak Peristalsis II | Screening | |
| Secondary | Number of Enrolled Participants With Anxiety and/or Depression | Screening | |
| Secondary | Number of Enrolled Participants With Functional Heartburn | Screening |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01265550/registered